These risk factors include blood pressure, cholesterol, and chronic inflammation [3]
And the results of that trial were published last August (2017): Title: Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial Authors: Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T Journal: Lancet 2017 Aug 3
instead, the dominant effect is mediated through altered carnitine availability ( Biotransformation and potential relevance of metabolites Most scientific publications focus on the parent compound [3-(2,2,2-trimethylhydrazinium) propionate], but biotransformation products may also be relevant
Although a loss in spectral information due to plasma treatment can be observed for all three iron complexes, the complexes are fairly stable during plasma treatment